Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer

An update and perspective among other treatments

Shilpa Gupta, Estrella Carballido, Mayer Fishman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally symptomatic prostate cancer. In this review we address the background of prostate cancer incidence and other available therapy onto which sipuleucel-T treatment has been added, with discussion of hormone-therapy, chemotherapy, and other investigational immunotherapies. The sipuleucel-T manufacturing process, toxicity and clinical benefit are reviewed, along with an examination of the issue of clinical benefit to survival, independent of apparent changes of prostate-specific antigen (PSA) levels. Sipuleucel-T therapy is appraised from clinician, patient and immunotherapeutic perspectives, with reference to the clinical data from the pivotal trial, the mechanism of action, and the treatment process.

Original languageEnglish (US)
Pages (from-to)79-96
Number of pages18
JournalOncoTargets and Therapy
Volume4
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Immunotherapy
Therapeutics
Drug Approval
Prostate-Specific Antigen
sipuleucel-T
Hormones
Drug Therapy
Food
Survival
Incidence

Keywords

  • Dendritic cells
  • Immunotherapy
  • Sipuleucel-T
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer : An update and perspective among other treatments. / Gupta, Shilpa; Carballido, Estrella; Fishman, Mayer.

In: OncoTargets and Therapy, Vol. 4, 2011, p. 79-96.

Research output: Contribution to journalArticle

@article{422e13f40e4545859767d90fdf59b57c,
title = "Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: An update and perspective among other treatments",
abstract = "Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally symptomatic prostate cancer. In this review we address the background of prostate cancer incidence and other available therapy onto which sipuleucel-T treatment has been added, with discussion of hormone-therapy, chemotherapy, and other investigational immunotherapies. The sipuleucel-T manufacturing process, toxicity and clinical benefit are reviewed, along with an examination of the issue of clinical benefit to survival, independent of apparent changes of prostate-specific antigen (PSA) levels. Sipuleucel-T therapy is appraised from clinician, patient and immunotherapeutic perspectives, with reference to the clinical data from the pivotal trial, the mechanism of action, and the treatment process.",
keywords = "Dendritic cells, Immunotherapy, Sipuleucel-T, Vaccine",
author = "Shilpa Gupta and Estrella Carballido and Mayer Fishman",
year = "2011",
doi = "10.2147/OTT.S14107",
language = "English (US)",
volume = "4",
pages = "79--96",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer

T2 - An update and perspective among other treatments

AU - Gupta, Shilpa

AU - Carballido, Estrella

AU - Fishman, Mayer

PY - 2011

Y1 - 2011

N2 - Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally symptomatic prostate cancer. In this review we address the background of prostate cancer incidence and other available therapy onto which sipuleucel-T treatment has been added, with discussion of hormone-therapy, chemotherapy, and other investigational immunotherapies. The sipuleucel-T manufacturing process, toxicity and clinical benefit are reviewed, along with an examination of the issue of clinical benefit to survival, independent of apparent changes of prostate-specific antigen (PSA) levels. Sipuleucel-T therapy is appraised from clinician, patient and immunotherapeutic perspectives, with reference to the clinical data from the pivotal trial, the mechanism of action, and the treatment process.

AB - Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally symptomatic prostate cancer. In this review we address the background of prostate cancer incidence and other available therapy onto which sipuleucel-T treatment has been added, with discussion of hormone-therapy, chemotherapy, and other investigational immunotherapies. The sipuleucel-T manufacturing process, toxicity and clinical benefit are reviewed, along with an examination of the issue of clinical benefit to survival, independent of apparent changes of prostate-specific antigen (PSA) levels. Sipuleucel-T therapy is appraised from clinician, patient and immunotherapeutic perspectives, with reference to the clinical data from the pivotal trial, the mechanism of action, and the treatment process.

KW - Dendritic cells

KW - Immunotherapy

KW - Sipuleucel-T

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84858797023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858797023&partnerID=8YFLogxK

U2 - 10.2147/OTT.S14107

DO - 10.2147/OTT.S14107

M3 - Article

VL - 4

SP - 79

EP - 96

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -